COPD Clinical Trial
Official title:
Cardiac Output and Brain Perfusion and Architecture During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Healthy, Age Matched Volunteers
Heart disease and conditions related to the blood vessels are responsible for a large
proportion (over a quarter) of the deaths in people with chronic obstructive pulmonary
disease (COPD). The changes can also affect the smaller smaller blood vessels within the
body, in particular the brain and the kidneys. This might be related to how the heart pumps
and if it is under any pressure. Investigations performed at the University in healthy older
volunteers demonstrated how the blood flows in the brain and heart during exercise. Exercise
gently puts the whole body under some pressure and therefore exposes any weaker areas.
In this study the investigators are hoping to find out what happens to the blood flow in the
brain and in the heart in patients who have COPD when they exercise and in the resting state.
This will be compared to people of a similar age with a similar smoking history but without
COPD. This will be examined using state of the art magnetic resonance imaging (MRI) and will
allow us to assess whether changes in structure and function are related to this altered
blood flow.
Our hypothesis is that COPD will cause a larger change in blood flow during exercise compared
to the healthy volunteers and that reduced cardiorespiratory fitness will be associated with
increased age related structural within the brain.
The aim is to recruit 20 participants with COPD, who will be compared to 10 age and gender
matched controls who also have a smoking history. The investigators aim for this number to
complete the components of the study and therefore may have to over-recruit if some people
drop out or are not eligible. The study elements are feasible, as the work extends a previous
research study in healthy volunteers.
This research trial will consist of a medical screening visit and three investigation study
visits spaced ideally one week apart. The investigation visits will begin within 6 (ideally
within 4) weeks of the medical screening visit. The total duration of the study and screening
visits should be 12 weeks maximum for each participant.
Screening visit:
If the participant expresses an interest in the clinical trial and wants to take part they
will be invited (at a convenient time for them) to attend a medical screening visit located
at the Nottingham City hospital. Here the investigator will discuss the research trial and
answer any questions or concerns they might have regarding the research trial. The
participant, if willing, will then be required to sign a consent form so that the screening
procedures can begin, which include:
- Blood sample: Approximately a 20ml sample (4 teaspoons) taken from their arm, for
further investigation including full blood count (FBC), brain natriuretic peptide (BNP)
and kidney function.
- Questionnaires: 5 different questionnaires that ask about symptoms and how they affect
daily life, a physical activity questionnaire, quality of life questionnaire and a MRI
safety questionnaire.
- Spirometry: A simple blowing test to assess the participants' breathing which is
performed three times.
- 12 lead ECG.
- a hand grip dynamometer to assess muscle strength
- timed up and go test: a test used to measure gait speed, where participants are asked to
get up from a chair and walking to 3 meters and back, whilst being timed.
- to wear a step counter (Sensewear armband) for a week during waking hours to record
steps.
Provided the ECG, step count (<10,000 steps) and other screening elements are ok, the
participant will proceed to Study visit 1.
Strength and exercise test protocol:
The participant will be required to abstain from strenuous exercise for the 48 hours prior to
the visit and also from alcohol and caffeine for 24 hours prior. Upon arrival they will
perform a knee extension exercise so we can establish the muscle strength in the legs,
specifically 3 maximal knee extensions with a 30 second rest in between. We will also measure
fatigue by dong 20 extensions after a short break.
After a break they will then undergo an exercise test using an MRI compatible stepper device
(Ergospect Cardiostepper) whilst in a supine position. This has been adapted to be similar to
how they will exercise in the MRI scanner. Volunteers will start off stepping at a frequency
of 65-70 steps a minute at the minimum workload and every 3 minutes get gradually a little
harder until exhaustion is reached. Heart rate at rest and in response to exercise will be
measured using a heart monitor. Participants will be given the option to have their expired
gases also measured during exercise using a face mask, though this is not necessary if not
tolerated. In the final minute of each workload we will take a finger prick test to measure
the gases in the patients blood. A 3 lead ECG and oxygen saturation probe will be attached
during exercise as safety measures and the protocol will be halted if oxygen saturation falls
below 80% or if any relevant rhythm abnormalities are seen on the ECG trace.
The second study visit will be used to confirm the exercise and strength parameters measured
in the first study visit.
MRI protocol:
A series of scans of the brain and heart will be taken at rest and then whilst stepping on
the stepper machine within the MRI. The exercise will be at a steady state low level
intensity determined by calculating the workload at which a fraction of maximum heart rate
was achieved during first 2 study visits.
The MRI scan itself will take about ¾ hour but upto 2 hours is allowed for preparation and
introducing the scan to the participant. The scanner is quite noisy and so the participant
will wear ear defenders during the scan. Because the scanner is built around a large magnet,
the participant will be instructed to remove all metal from their body, including jewellery.
There is no radiation involved.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |